Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
Nuvau Announces Voting Results of Its Annual and Special Meeting of Shareholders and Announces the Appointment of Steven Bowles as Chair of the Board
SAGA Metals Appoints Accomplished Mining Executive Peter Hogendoorn to Board of Advisors and Engages Xander Capital Partners
Blue Lagoon Announces Major Steps Toward Production: Fully Funded, Government Inspections Passed, and Water Treatment Plant Completed